Global Dupilumab Injection Market Growth 2024-2030

Publication ID:

LPI08240246

Publication Date:

August 1, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Dupilumab is a monoclonal antibody drug that belongs to the class of immunosuppressants and is used to treat a variety of inflammatory diseases. It mainly works by targeting and inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that play an important role in a variety of inflammatory responses.
The global Dupilumab Injection market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淒upilumab Injection Industry Forecast鈥� looks at past sales and reviews total world Dupilumab Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Dupilumab Injection sales for 2024 through 2030. With Dupilumab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dupilumab Injection industry.
This Insight Report provides a comprehensive analysis of the global Dupilumab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dupilumab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Dupilumab Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dupilumab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dupilumab Injection.
United States market for Dupilumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Dupilumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Dupilumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Dupilumab Injection players cover Regeneron, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Dupilumab Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
200mg (1.14mL)/Vial
300mg (2.0 mL)/Vial
Segmentation by Application:
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Regeneron
Sanofi
Key Questions Addressed in this Report
What is the 10-year outlook for the global Dupilumab Injection market?
What factors are driving Dupilumab Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dupilumab Injection market opportunities vary by end market size?
How does Dupilumab Injection break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dupilumab Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Dupilumab Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Dupilumab Injection by Country/Region, 2019, 2023 & 2030
2.2 Dupilumab Injection Segment by Type
2.2.1 200mg (1.14mL)/Vial
2.2.2 300mg (2.0 mL)/Vial
2.3 Dupilumab Injection Sales by Type
2.3.1 Global Dupilumab Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Dupilumab Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Dupilumab Injection Sale Price by Type (2019-2024)
2.4 Dupilumab Injection Segment by Application
2.4.1 Atopic Dermatitis
2.4.2 Asthma
2.4.3 Chronic Sinusitis with Nasal Polyps
2.4.4 Other
2.5 Dupilumab Injection Sales by Application
2.5.1 Global Dupilumab Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Dupilumab Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Dupilumab Injection Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Dupilumab Injection Breakdown Data by Company
3.1.1 Global Dupilumab Injection Annual Sales by Company (2019-2024)
3.1.2 Global Dupilumab Injection Sales Market Share by Company (2019-2024)
3.2 Global Dupilumab Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Dupilumab Injection Revenue by Company (2019-2024)
3.2.2 Global Dupilumab Injection Revenue Market Share by Company (2019-2024)
3.3 Global Dupilumab Injection Sale Price by Company
3.4 Key Manufacturers Dupilumab Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dupilumab Injection Product Location Distribution
3.4.2 Players Dupilumab Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Dupilumab Injection by Geographic Region
4.1 World Historic Dupilumab Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Dupilumab Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Dupilumab Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Dupilumab Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Dupilumab Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Dupilumab Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Dupilumab Injection Sales Growth
4.4 APAC Dupilumab Injection Sales Growth
4.5 Europe Dupilumab Injection Sales Growth
4.6 Middle East & Africa Dupilumab Injection Sales Growth
5 Americas
5.1 Americas Dupilumab Injection Sales by Country
5.1.1 Americas Dupilumab Injection Sales by Country (2019-2024)
5.1.2 Americas Dupilumab Injection Revenue by Country (2019-2024)
5.2 Americas Dupilumab Injection Sales by Type (2019-2024)
5.3 Americas Dupilumab Injection Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dupilumab Injection Sales by Region
6.1.1 APAC Dupilumab Injection Sales by Region (2019-2024)
6.1.2 APAC Dupilumab Injection Revenue by Region (2019-2024)
6.2 APAC Dupilumab Injection Sales by Type (2019-2024)
6.3 APAC Dupilumab Injection Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Dupilumab Injection by Country
7.1.1 Europe Dupilumab Injection Sales by Country (2019-2024)
7.1.2 Europe Dupilumab Injection Revenue by Country (2019-2024)
7.2 Europe Dupilumab Injection Sales by Type (2019-2024)
7.3 Europe Dupilumab Injection Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dupilumab Injection by Country
8.1.1 Middle East & Africa Dupilumab Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Dupilumab Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Dupilumab Injection Sales by Type (2019-2024)
8.3 Middle East & Africa Dupilumab Injection Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dupilumab Injection
10.3 Manufacturing Process Analysis of Dupilumab Injection
10.4 Industry Chain Structure of Dupilumab Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dupilumab Injection Distributors
11.3 Dupilumab Injection Customer
12 World Forecast Review for Dupilumab Injection by Geographic Region
12.1 Global Dupilumab Injection Market Size Forecast by Region
12.1.1 Global Dupilumab Injection Forecast by Region (2025-2030)
12.1.2 Global Dupilumab Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Dupilumab Injection Forecast by Type (2025-2030)
12.7 Global Dupilumab Injection Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Regeneron
13.1.1 Regeneron Company Information
13.1.2 Regeneron Dupilumab Injection Product Portfolios and Specifications
13.1.3 Regeneron Dupilumab Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Regeneron Main Business Overview
13.1.5 Regeneron Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Dupilumab Injection Product Portfolios and Specifications
13.2.3 Sanofi Dupilumab Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂